Transition Therapeutics Enters Osteoarthritis License and Collaboration Agreement with Lilly

Transition Therapeutics Enters Osteoarthritis License and Collaboration 
Agreement with Lilly 
TORONTO, July 23, 2013 /CNW/ - Transition Therapeutics Inc. ("Transition" or 
the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the exclusive 
licensing of worldwide rights to a novel small molecule transcriptional 
regulator ("TT-601") from Eli Lilly and Company for the treatment of 
osteoarthritis ("OA") pain. TT-601 is a potent and selective ligand for a 
novel nuclear receptor target. Modulating the activity of this novel target in 
patients with osteoarthritis may provide pain relief to a large segment of OA 
patients who do not have adequate response to therapy with NSAIDs 
(non-steroidal anti-inflammatory drugs).  TT-601 has completed preclinical 
development to date and Transition anticipates can enter the clinic in the 
first half of 2014. 
"We are very pleased with the opportunity to continue our relationship with 
Lilly through the in-licensing of TT-601. Molecules in this novel class have 
shown target engagement in the joint space and efficacy in multiple animal 
models of joint pain. We look forward to TT-601 clinical studies as this 
drug candidate has the potential to provide an important new source of pain 
relief to the more than 27 million Americans suffering from OA", said Dr. Tony 
Cruz, Chairman and Chief Executive Officer of Transition. 
Under the terms of the agreement, Transition has acquired the rights to 
develop and potentially commercialize TT-601. Lilly retains an option to 
reacquire all rights to TT-601 following review of clinical proof-of-concept 
study results. If Lilly exercises this option right, Transition would be 
eligible to receive milestone payments of approximately US$130 million and a 
high single-digit royalty on sales of products containing TT-601 should such 
products be successfully commercialized. If Lilly does not exercise this 
option right, Lilly would be eligible for a low single-digit royalty from 
Transition on sales of products containing TT-601 should such products be 
successfully commercialized. 
About Osteoarthritis (OA) 
OA is the most common form of arthritis and is a chronic condition 
characterized by the breakdown of the joint's cartilage. Cartilage is the part 
of the joint that cushions the ends of the bones and allows easy movement of 
joints. The breakdown of cartilage causes the bones to rub against each other, 
causing stiffness, pain and loss of movement in the joint. The joints most 
commonly affected are the knees, hips, and those in the hands and spine. 
An estimated 27 million Americans live with OA, with almost one third of 
people over the age of 65 affected by OA. Key risk factors for OA include 
age, obesity, injury or overuse and genetics. There is currently no cure for 
OA. Available therapeutics focus on pain relief and include acetaminophen, 
NSAIDs, and opioids. 
About Transition 
Transition is a biopharmaceutical company, developing novel therapeutics for 
disease indications with large markets. The Company's lead CNS drug candidate 
is ELND005 for the treatment of Alzheimer's disease and bipolar disorder. 
Transition's lead metabolic drug candidate is TT-401 for the treatment of type 
2 diabetes and accompanying obesity. The Company's shares are listed on the 
NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol 
"TTH". For additional information about the Company, please visit 
Notice to Readers: Information contained in our press releases should be 
considered accurate only as of the date of the release and may be superseded 
by more recent information we have disclosed in later press releases, filings 
with the OSC, SEC or otherwise. Except for historical information, this press 
release may contain forward-looking statements, relating to expectations, 
plans or prospects for Transition, including conducting clinical trials and 
potential efficacy of its products. These statements are based upon the 
current expectations and beliefs of Transition's management and are subject to 
certain risks and uncertainties that could cause actual results to differ 
materially from those described in the forward-looking statements. These risks 
and uncertainties include factors beyond Transition's control and the risk 
factors and other cautionary statements discussed in Transition's quarterly 
and annual filings with the Canadian commissions. 
on Transition, or contact: 
Dr. Tony Cruz Chief Executive Officer Transition Therapeutics Inc. Phone: 
416-260-7770, x.223 
SOURCE: Transition Therapeutics Inc. 
To view this news release in HTML formatting, please use the following URL: 
CO: Transition Therapeutics Inc.
ST: Ontario
-0- Jul/23/2013 20:44 GMT
Press spacebar to pause and continue. Press esc to stop.